Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ThermoGenesis fibrin sealant proves effective
The pivotal 150-patient, multi-center trial was designed to evaluate the safety and efficacy of the fibrin sealant prepared by ThermoGenesis’s CryoSeal FS System as an adjunct to hemostasis
The pivotal 150-patient, multi-center trial was designed to evaluate the safety and efficacy of the fibrin sealant prepared by ThermoGenesis’s CryoSeal FS System as an adjunct to hemostasis
The study by University College London (UCL) and King’s College London suggests that in everyday life, schizophrenics take less account of visual context. If this is part of
The compound, OGX-011, is a second-generation antisense drug designed to specifically inhibit the production of clusterin, a cell-survival protein associated with resistance to standard anticancer treatments. The clinical
The two organizations will work together using Affymetrix’ GeneChip microarray technology and CureSearch Children’s Oncology Group’s (COG’s) existing databank of more than 20,000 tumor samples to discover and
It is hoped PRO 2000 will prove effective in tackling infections such as HIV, herpes, chlamydia and gonorrhea. The trial, which is sponsored by the Medical Research Council
Aroplatin is a liposomal formulation of a proprietary platinum chemotherapeutic. The dose-ranging study will evaluate the safety and pharmacokinetic profile of Aroplatin, which has been reformulated to enhance
The study is evaluating Albuferon (albumin-interferon alpha) in combination with ribavirin in patients who are naive to interferon alpha- based treatment regimens. According to Human Genome, Genotype 1
PharmacoDesign will genotype various Korean populations with the aim of understanding genetic variation and personalizing treatment for optimal clinical outcomes. Under the agreement, Illumina will gain access to
The companies were already aware that there was a possibility the drug may cause liver abnormalities and had ended previous phase II studies being conducted in treatment-naive patients,
The team will be responsible for working with industry, academia and other government agencies to increase the manufacture of anti-influenza drug oseltamivir phosphate (tamiflu) and support clinical studies